Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response

Randomized clinical trials demonstrated that CDK4/6 inhibitors are highly effective in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer in combination with endocrine therapy. The use of CDK4/6 inhibitors in clinics is becoming common for patients with HR+...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Care (Basel)
Hlavní autoři: Guarducci, Cristina, Bonechi, Martina, Boccalini, Giulia, Benelli, Matteo, Risi, Emanuela, Di Leo, Angelo, Malorni, Luca, Migliaccio, Ilenia
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger GmbH 2017
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5704709/
https://ncbi.nlm.nih.gov/pubmed/29234249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000484167
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky